These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28274680)

  • 21. Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial insulin glulisine.
    Ohta A; Arai K; Nishine A; Sada Y; Kato H; Fukuda H; Asai S; Nagai Y; Katabami T; Tanaka Y
    Endocr J; 2013; 60(2):173-7. PubMed ID: 23047542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
    Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
    Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Basal-Bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes.
    Bellido V; Suarez L; Rodriguez MG; Sanchez C; Dieguez M; Riestra M; Casal F; Delgado E; Menendez E; Umpierrez GE
    Diabetes Care; 2015 Dec; 38(12):2211-6. PubMed ID: 26459273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiating basal insulin.
    Zhou FL; Xie L; Pan C; Wang Y; Vaidya N; Ye F; Preblick R; Meneghini L
    Diabetes Obes Metab; 2018 May; 20(5):1298-1301. PubMed ID: 29278460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1).
    Matsuhisa M; Koyama M; Cheng X; Takahashi Y; Riddle MC; Bolli GB; Hirose T;
    Diabetes Obes Metab; 2016 Apr; 18(4):375-83. PubMed ID: 26662964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved glycemic control and acute complications among children with type 1 diabetes mellitus in Moshi, Tanzania.
    Mukama LJ; Moran A; Nyindo M; Philemon R; Msuya L
    Pediatr Diabetes; 2013 May; 14(3):211-6. PubMed ID: 23350587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HYPOGLYCEMIA RATES AFTER RESTRICTION OF HIGH-DOSE GLARGINE IN HOSPITALIZED PATIENTS.
    Lee SY; Askin G; McDonnell ME; Arnold LM; Alexanian SM
    Endocr Pract; 2016 Dec; 22(12):1393-1400. PubMed ID: 27540877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study.
    Escalada J; Bonnet F; Wu J; Bonnemaire M; Gupta S; Cambron-Mellott JM; Nicholls C; Müller-Wieland D
    Adv Ther; 2020 Sep; 37(9):3863-3877. PubMed ID: 32681460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HYPERGLYCEMIA AND HYPOGLYCEMIA IN PATIENTS WITH DIABETES IN SKILLED NURSING FACILITIES.
    Patell R; Nigmatoulline D; Bena J; Kim DG; Messinger-Rapport B; Lansang MC
    Endocr Pract; 2017 Apr; 23(4):458-465. PubMed ID: 28156156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intraperitoneal insulin delivery provides superior glycaemic regulation to subcutaneous insulin delivery in model predictive control-based fully-automated artificial pancreas in patients with type 1 diabetes: a pilot study.
    Dassau E; Renard E; Place J; Farret A; Pelletier MJ; Lee J; Huyett LM; Chakrabarty A; Doyle FJ; Zisser HC
    Diabetes Obes Metab; 2017 Dec; 19(12):1698-1705. PubMed ID: 28474383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
    Yang W; Min K; Zhou Z; Li L; Xu X; Zhu D; Venkateshwar Rao A; Murthy LS; Zhang N; Li I; Niemoeller E; Shang S
    Diabetes Obes Metab; 2018 Feb; 20(2):335-343. PubMed ID: 28742225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes.
    Riddle MC; Bolli GB; Home PD; Bergenstal RM; Ziemen M; Muehlen-Bartmer I; Wardecki M; Vinet L; Jeandidier N; Yki-Järvinen H
    Diabetes Technol Ther; 2016 Apr; 18(4):252-7. PubMed ID: 26840338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
    Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z
    Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study.
    Blevins TC; Barve A; Sun B; Ankersen M
    Diabetes Obes Metab; 2018 Aug; 20(8):1944-1950. PubMed ID: 29656504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus.
    Karl DM; Gill J; Zhou R; Riddle MC
    Diabetes Obes Metab; 2013 Jul; 15(7):622-8. PubMed ID: 23350795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the efficacy and safety of insulin degludec/aspart (twice-daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal-bolus therapy).
    Kawaguchi Y; Sawa J; Hamai C; Nishimura Y; Kumeda Y
    J Diabetes Investig; 2019 Nov; 10(6):1527-1536. PubMed ID: 30868726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.
    Mathieu C; Bode BW; Franek E; Philis-Tsimikas A; Rose L; Graungaard T; Birk Østerskov A; Russell-Jones D
    Diabetes Obes Metab; 2018 May; 20(5):1148-1155. PubMed ID: 29316130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicenter, open-label, nonrandomized, observational safety study in subjects using insulin aspart in basal-bolus regimen for the treatment of diabetes.
    Krzymień J; Kobli T; Nazar M
    Pol Arch Med Wewn; 2010 Nov; 120(11):444-50. PubMed ID: 21102380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-World Health Outcomes of Insulin Glargine 300 U/mL vs Insulin Glargine 100 U/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study.
    Abitbol A; Brown RE; Jiandani D; Sauriol L; Aronson R
    Can J Diabetes; 2019 Oct; 43(7):504-509.e1. PubMed ID: 31256905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.